Tetra Bio-Pharma acquires Canadian rights to Dronabinol Soft Gel capsules, adding to top-line growth

Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) Chief Commercial Officer Steeve Néron tells Proactive the biotech has acquired the Canadian exclusive rights for Dronabinol Soft Gel capsules, cannabinoid derived prescription drug aimed to treat AIDS-related anorexia and severe nausea and vomiting associated with chemotherapy. Néron says the acquisition will allow Tetra to establish an immediate and direct commercial presence in Canada, adding to the group's top-line growth, giving it the capital to fuel its drug development program.